Literature DB >> 11697582

Erythropoietin--a novel concept for neuroprotection.

A L Sirén1, H Ehrenreich.   

Abstract

Neuroprotection as a means to prevent or oppose pathological neuronal loss in central nervous system disease of various pathophysiological origins represents a novel therapeutic approach. This approach is supported by extensive experimental evidence on cell culture and animal studies demonstrating beneficial effects of growth factors on neuronal survival and functional recovery. The clinical use of neuroprotective agents has been hampered by the toxicity of many of the compounds that showed promising therapeutic potential in animal studies. The focus of this review is on a novel neuroprotective approach with erythropoietin, a hematopoietic growth factor that: 1) is expressed in the human central nervous system, 2) is hypoxia-inducible, 3) has demonstrated remarkable neuroprotective potential in cell culture and animal models of disease, 4) has multiple protective effects (antiapoptotic, neurotrophic, antioxidant, angiogenic), and 5) is a clinically extremely well tolerated compound.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11697582     DOI: 10.1007/s004060170038

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  35 in total

Review 1.  A Distinct Region in Erythropoietin that Induces Immuno/Inflammatory Modulation and Tissue Protection.

Authors:  RuiRong Yuan; Bo Wang; Wei Lu; Yasuhiro Maeda; Peter Dowling
Journal:  Neurotherapeutics       Date:  2015-10       Impact factor: 7.620

2.  Erythropoietin: still on the neuroprotection road.

Authors:  Nelvys Subirós; Diana García Del Barco; Rosa M Coro-Antich
Journal:  Ther Adv Neurol Disord       Date:  2012-05       Impact factor: 6.570

3.  White matter changes in patients with friedreich ataxia after treatment with erythropoietin.

Authors:  Karl Egger; Christian Clemm von Hohenberg; Michael F Schocke; Charles R G Guttmann; Demian Wassermann; Marlene C Wigand; Wolfgang Nachbauer; Christian Kremser; Brigitte Sturm; Barbara Scheiber-Mojdehkar; Marek Kubicki; Martha E Shenton; Sylvia Boesch
Journal:  J Neuroimaging       Date:  2013-09-09       Impact factor: 2.486

Review 4.  Clinical trials for cytoprotection in stroke.

Authors:  Lise A Labiche; James C Grotta
Journal:  NeuroRx       Date:  2004-01

5.  Low-oxygen culture conditions extend the multipotent properties of human retinal progenitor cells.

Authors:  Petr Y Baranov; Budd A Tucker; Michael J Young
Journal:  Tissue Eng Part A       Date:  2014-01-24       Impact factor: 3.845

6.  Neuroprotective activities of enzymatically hydrolyzed peptides from porcine hide gelatin.

Authors:  Shaoyun Wang; Deng-Shun Wang; Rui Wang
Journal:  Int J Clin Exp Med       Date:  2008-08-10

7.  Erythropoietin protects the intestine against ischemia/ reperfusion injury in rats.

Authors:  Ensari Guneli; Zahide Cavdar; Huray Islekel; Sulen Sarioglu; Serhat Erbayraktar; Muge Kiray; Selman Sokmen; Osman Yilmaz; Necati Gokmen
Journal:  Mol Med       Date:  2007 Sep-Oct       Impact factor: 6.354

Review 8.  Progress in neuroprotective strategies for preventing epilepsy.

Authors:  Munjal M Acharya; Bharathi Hattiangady; Ashok K Shetty
Journal:  Prog Neurobiol       Date:  2007-12-08       Impact factor: 11.685

9.  Safety of intravitreally administered recombinant erythropoietin (an AOS thesis).

Authors:  James C Tsai
Journal:  Trans Am Ophthalmol Soc       Date:  2008

10.  Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases.

Authors:  Douglas B Kell
Journal:  BMC Med Genomics       Date:  2009-01-08       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.